Referencias

1. Turpie AGG, Levine MAI, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull R, Gent M. A randomized controlled trial of a low molecular weight Heparin (Enoxaparín) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315 : 925-9.

2. Planes A, Vochelle N, Ferru J, Przyrowski D, Clere J, Fagola M, Planes M. Enoxaparin. Low Molecular Weight Heparin: Its use in the prevention of deep venous thrombosis following total hip replacement. Haemostasis 1986; 16:152- 8.

3. Planes A, Vochelle N, Mansat C, Prevention of deep vein thrombosis after total hip replacement by Enoxaparin. One dafly injection of 40 mg versus two daily injections of 20 mg. Thromb Haemostas 1987; 58 .Abstract.

4. Morris GK Henry APJ, Preston BJ. Prevention of deep-vein thrombosis by low- dose heparin in patients undergoing total hip replacement. Lancet 1974; 2:797-9.

5. Mannucci PM, Citterio LE, Panajotopoulos N. Low dose heparin and deep vein thrombosis after total hip replacement. Thromb Haemostas 1976; 36:157-64.

6. Venous Thrombosis Clinical Stuay Group. Small doses of subcutaneous sodium heparin in the prevention of deep vein thrombosis after electivo hip operations. Br J Surg 1975; 62:348-50.

7. Moskovitz PA, Ellenberg SS, Feffer HL, Kenmore PI, Neviaser RJ, Rubin BE, Varma VM. Low dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg (AM) 1978; 60:1065-70,

8, Decha vanne M, Saudin F, Viala JJ, Kher A, Bertrix L, De Mourgues G. Prévention des thromboses veineuses. Succés de l'heparine a fortes doses lors des coxarthroses. Nouv Presse Med 1974, 3:1317-9.

9. Gallus AS, Hirsh J, Tuttle RJ, Trebilcok R. O'Brien ST, Carrol Jj Minden JH, Hudecki SM. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973; 288:545-5 1.

10. Hampson WG, Harris FC, Keith Lucas H, Roberts PH, McCall /W Jackson PC, Powell NL, Staddon GE Failure of Low-dose heparin to prevent deep vein thrombosis after hip-replacement arthroplasty. Lancet 1974; 2:795-7.

11. Hume M, Kuriakose TX, Zuch L, Tumer RH. 1-fibrinogen and the prevention of venous thrombosis. Arch Surg 1973, 107:803-6

12. Carter CJ, KeIton JG, Hirsh J, Cerskus A, Santos A V, Gent M. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982, 59:1239-45.

13. Zachrisson BE, Jansen HJ. Phlebograjohic signs in fresh post-operative venous thrombosis of the lower extremity. Acta Radiol (Diagn) (Strockh) 1973; 14:82-96.

14. Hull R, Hirsh J, Jay R, Carter C, England CY, Gent M, Turpie AGG, McLoughlin D, Dood P, Thomas M, Rascob G, Ocke1ford P. Different intensities of oral anticoagulant Therapy in the treatment of proximal vein thrombosis. N Engl J Med 1982; 307: 1676-81.

15. Hirsh J, Genton E, Hull R. Venous Thromboembolism. Grune and Stratton 1981, pp 114-5. 16. Bergquist D. Post Operative Thrombo-embolism. Springer Verlag. Berlin 1983, pp 16-22.

17. Francis CW, Marder VJ, Evarts CM. Yaukoolbodi S. Two-step warfarin therapy. Prevention of post-operative venous thrombosis without excessive bleeding. JAMA 1983; 249:374-8.

18. Paiment GD, Bell D. Weissinger SJ, Harris WH. New advances in the prevention, diagnosis and cost effectiveness of venous thromboembolic disease in patients with total hip replacement. In: The Hip-Proceedings of the Hip Society. Mosby 1986 pp. 94-119.

19. Leyvraz PF, Richard J, Backmann F, van Melle G, Treyvaud JM, Livig JJ, Candarjis G. Adjusted versus fixed dose subcutaneous Heparin in the prevention of deep vein thrombosis atter total hip replacement. N Engl J Med 1983; 309:954-8.

20. Aiach M, Michaud A, Balian A, Lefebvre M, Woler M, Fourtillan J. A new low molecular weight heparin derivative: in vitro and in vivo study. Thromb Res 1983; 31:611-2 1.

21. Vinazzer H, Woler M. A New Low Molecular Weight Heparin Fragment PK10169). In vitro and in vivo studies. Haemostasis 1986; 16:106-15,

22. Dawes J, Bara L, Billaud E, Samama M, Relationship between biological activity and concentration of a low molecular weight heparin PK10 169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 1986; 16:116-22.

23. Fareed J, Walenga JM, Hoppenstead DA, Martin Emanuele R. Laboratory Studies on the intravenous and subcutaneous administration of PK 10 169 in man. Haemostasis 1986; 16:123~3&

24. Bara L, Le Roux Y, Woler M. Chauliac F, Frydman A, Samama M, Pharmacokinetics of Enoxaparin after single subcutaneous administration of increasing doses (20 up to 80 rng) to healthy volunteers. Thromb Hemostas 1987; 58:117 (417, Abstr).

25. Francis CW, Marder VJ, Evarts CM. Lower risk of thromboembolic disease alter total hip replacement with non cemented than with cementeo`prostheses. Lancet 1986, 1: 769-71.